POPULARITY
Categories
57 episodes with Targeted therapy
35 episodes with Targeted therapy
43 episodes with Targeted therapy
43 episodes with Targeted therapy
39 episodes with Targeted therapy
39 episodes with Targeted therapy
57 episodes with Targeted therapy
31 episodes with Targeted therapy
41 episodes with Targeted therapy
31 episodes with Targeted therapy
37 episodes with Targeted therapy
14 episodes with Targeted therapy
13 episodes with Targeted therapy
38 episodes with Targeted therapy
13 episodes with Targeted therapy
9 episodes with Targeted therapy
13 episodes with Targeted therapy
9 episodes with Targeted therapy
13 episodes with Targeted therapy
7 episodes with Targeted therapy
6 episodes with Targeted therapy
11 episodes with Targeted therapy
6 episodes with Targeted therapy
10 episodes with Targeted therapy
4 episodes with Targeted therapy
7 episodes with Targeted therapy
3 episodes with Targeted therapy
3 episodes with Targeted therapy
3 episodes with Targeted therapy
4 episodes with Targeted therapy
10 episodes with Targeted therapy
3 episodes with Targeted therapy
4 episodes with Targeted therapy
10 episodes with Targeted therapy
2 episodes with Targeted therapy
4 episodes with Targeted therapy
BUFFALO, NY – July 9, 2025 – A new #review was #published in Volume 16 of Oncotarget on June 25, 2025, titled “Challenges and resistance mechanisms to EGFR targeted therapies in head and neck cancers and breast cancer: Insights into RTK dependent and independent mechanisms.” Researchers from the University of Cincinnati and Cincinnati Veterans Affairs Medical Center reviewed current research on why Epidermal Growth Factor Receptor (EGFR)-targeted therapies often fail in breast and head and neck cancers. The article by Shreya Shyamsunder, Zhixin Lu, Vinita Takiar, and Susan E. Waltz explores how cancer cells evade these treatments by activating alternative survival pathways. This review offers an in-depth look at the molecular barriers to EGFR inhibition and provides insights that could inform the development of more effective and durable treatments. EGFR is a critical protein that regulates cell growth and survival, and it is frequently overexpressed in breast and head and neck cancers. Although therapies targeting EGFR showed early promise, resistance has become a significant challenge. In breast cancer, resistance mechanisms include the movement of EGFR from the cell surface into the nucleus, where it promotes DNA repair, as well as ligand-dependent activation that helps tumor growth despite therapy. In head and neck cancers, resistance often arises from inflammatory signaling through the TLR4-MyD88 pathway and the loss of tumor suppressor genes like PTEN, which allow cancer cells to bypass EGFR inhibition. The review also describes how tumor cells in both cancers commonly activate other receptor tyrosine kinases (RTKs), such as MET, AXL, and RON, to continue growing even when EGFR is blocked. By analyzing these resistance mechanisms, the authors highlight combination therapies from current research that target EGFR and other key molecular pathways. Strategies such as dual inhibition of EGFR and MET or blocking inflammation-driven survival signals may enhance treatment outcomes. Several clinical trials are evaluating these approaches in patients. For example, in breast cancer, combinations of EGFR inhibitors with chemotherapy and immune checkpoint inhibitors are being tested to improve responses, particularly in triple-negative breast cancer. In head and neck cancers, trials are investigating EGFR-blocking antibodies like cetuximab combined with immunotherapies such as pembrolizumab and nivolumab. These efforts aim to overcome resistance and provide more effective treatment options for patients with EGFR-driven tumors. The review also emphasizes the necessity of identifying biomarkers to predict which patients are most likely to benefit from EGFR-based therapies. “A recent phase 1 study has shown that patients with recurrent or metastatic head and neck cancer who received BCA101, a bifunctional dual targeting drug that targets EGFR and TGF-β in combination with pembrolizumab, were able to achieve an overall response rate of 65%.” This work brings together current knowledge about EGFR resistance and illustrates the difficulties involved in treating breast and head and neck cancers. By mapping the many ways tumors overcome EGFR inhibition, the review highlights opportunities for more tailored and effective treatments in the future. DOI - https://doi.org/10.18632/oncotarget.28747 Correspondence to - Susan E. Waltz - susan.waltz@uc.edu, and Vinita Takiar - takiarva@ucmail.uc.edu Video short - https://www.youtube.com/watch?v=RD2W-F3_aX4 About Oncotarget: Website - https://www.oncotarget.com Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
In this enlightening episode of Keeping Abreast, Dr. Jenn sits down with world-renowned surgical oncologist Dr. Francisco Contreras to explore how mindset, metabolic therapy, and integrative medicine can change the cancer care conversation.Guided by the influence of his father, a pioneer in holistic oncology, Dr. Contreras shares his path to becoming a surgeon and his mission to treat not just the disease, but the whole person. From patient empowerment to the limitations of conventional care, this episode offers a deep dive into the emotional, spiritual, and metabolic components of healing.You'll hear how innovative therapies at Oasis of Hope combine conventional medicine with holistic practices—and why patient education is the cornerstone of long-term success.This conversation is filled with hope, science, and practical insights to help you take charge of your healing journey.In This Episode, You Will Learn:How Dr. Contreras's father inspired his holistic cancer care approachWhy mindset and empowerment are critical in healingThe science behind metabolic therapy and low-glycemic nutritionWhat immunotherapy is—and how it's changing cancer outcomesHow alternative and conventional treatments can work togetherWhy movement, habit-building, and diet play vital roles in recoveryThe truth about high-dose vitamin C, off-label meds, and natural remediesHow innovative treatments like dendritic cell vaccines and CAR T cells workWhy patients deserve education, options, and hope
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
In this episode of Hema Now, host Jonathan Sackier is joined by Kevin Rouault-Pierre and Onima Chowdhury, to explore the biological mechanisms behind MDS, with a spotlight on SF3B1 mutations. From epigenetic stress to diagnostic strategies, this discussion bridges laboratory research and frontline care. Timestamps 01:11 – Quickfire Round 07:11 – Haematology Misconceptions 10:56 – Understanding MDS 18:42 – Treating Myeloid Malignancies 23:20 – Epigenetic Mechanisms 28:30 – MDS Treatment Approaches 34:56 – Three Wishes
Lydia Scarfò is a Physician Scientist at the B-cell Neoplasia Unit and an Assistant Professor at Università Vita-Salute San Raffaele, Milan, Italy. She is involved in both clinical and pre-clinical studies, including being a co-investigator in over 20 clinical trials in haematological malignancies, including chronic lymphocytic leukaemia. Timestamps: 0:00 – Introduction 1:14 – Quickfire questions 7:31 – Haematology inspiration 9:08 – STIL loss 11:42 – Splenic marginal zone lymphoma 13:03 – Novel targeted therapies for chronic lymphocytic leukaemia 17:35 – Covalent BTK inhibitors 19:30 – Chemo-free approach for hairy cell leukaemia 22:20 – Recent advances, challenges, and opportunities 25:58 – Three wishes
When your doctor says you need “cancer treatment,” do you know what that actually means?Most people immediately think of chemotherapy. But if you or someone you love is facing a cancer diagnosis, understanding the full range of treatment options could be the difference between feeling overwhelmed and feeling empowered.Dr. Katie Deming sits down with Dr. Jason Konner, a medical oncologist at Memorial Sloan Kettering Cancer Center, to break down the three main types of systemic cancer treatment used today: chemotherapy, targeted therapies, and immunotherapies.Chapters:03:43 – Three Main Types of Cancer Treatment16:34 – Why First-Line Therapies Matter20:48 – Combining Holistic and Conventional Care31:23 – Essential Questions to Ask Your Oncologist43:42 – When and Why to Seek a Second OpinionDr. Konnor shares the insider perspective on second opinions, what those complex drug names really mean, and how to build the kind of relationship with your medical team that leads to better outcomes.You'll learn how some patients unknowingly sabotage their own care and what questions can instantly make you a more informed patient. Listen and learn how to walk into any oncologist's office with confidence, ask the right questions, and truly understand your options.Don't let medical jargon and complex choices keep you in the dark when clear thinking matters most.Reserve Your Spot for the June PSYCH-K® Online Workshop: https://www.katiedeming.com/psych-k-june-2025 Transform your hydration with the system that delivers filtered, mineralized, and structured water all in one. Spring Aqua System: https://springaqua.info/drkatieMORE FROM KATIE DEMING M.D. Download Your Free Webinar & Ultimate Guide to Water Fasting to Heal Cancer and Chronic Illness https://www.katiedeming.com/prolonged-water-fasting/ Work with Dr. Katie: www.katiedeming.comEmail: INFO@KATIEDEMING.COM 6 Pillars of Healing Cancer Workshop Series - Click Here to Enroll Follow Dr. Katie Deming on Instagram: https://www.instagram.com/katiedemingmd/ Please Support the Show Share this episode with a friend or family member Give a Review on Spotify Give a Review on Apple Podcast DISCLAIMER: The Born to Heal Podcast is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose, treat, cure, or prevent any disease without consulting your healthcare provider.
Commentary by Kazuhiro Sase.
Stephen V. Liu, MD and Susan C. Scott, MD discuss advances in treating HER2-mutant lung cancer. Until recently, treatments for HER2-mutant lung cancer primarily involved chemotherapy, immunotherapy, and HER2-targeted therapies, with mixed results. Now, the treatment landscape of HER2-mutant lung cancer is changing.
View Activity Information…
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/UKV865. CME/MOC/CC/AAPA credit will be available until June 13, 2026.Harnessing Precision With EGFR-Targeted Therapy in Resectable NSCLC: Evidence, Cases, and Considerations for Multidisciplinary Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/UKV865. CME/MOC/CC/AAPA credit will be available until June 13, 2026.Harnessing Precision With EGFR-Targeted Therapy in Resectable NSCLC: Evidence, Cases, and Considerations for Multidisciplinary Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/UKV865. CME/MOC/CC/AAPA credit will be available until June 13, 2026.Harnessing Precision With EGFR-Targeted Therapy in Resectable NSCLC: Evidence, Cases, and Considerations for Multidisciplinary Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/UKV865. CME/MOC/CC/AAPA credit will be available until June 13, 2026.Harnessing Precision With EGFR-Targeted Therapy in Resectable NSCLC: Evidence, Cases, and Considerations for Multidisciplinary Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/UKV865. CME/MOC/CC/AAPA credit will be available until June 13, 2026.Harnessing Precision With EGFR-Targeted Therapy in Resectable NSCLC: Evidence, Cases, and Considerations for Multidisciplinary Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/UKV865. CME/MOC/CC/AAPA credit will be available until June 13, 2026.Harnessing Precision With EGFR-Targeted Therapy in Resectable NSCLC: Evidence, Cases, and Considerations for Multidisciplinary Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
Maria Dall'Era, MD - When They Need Targeted Therapy: Selecting the Optimal Treatment Approach for Lupus Nephritis in an Evolving Treatment Landscape
Maria Dall'Era, MD - When They Need Targeted Therapy: Selecting the Optimal Treatment Approach for Lupus Nephritis in an Evolving Treatment Landscape
Maria Dall'Era, MD - When They Need Targeted Therapy: Selecting the Optimal Treatment Approach for Lupus Nephritis in an Evolving Treatment Landscape
Maria Dall'Era, MD - When They Need Targeted Therapy: Selecting the Optimal Treatment Approach for Lupus Nephritis in an Evolving Treatment Landscape
In this episode of the Oncology Brothers podcast, Drs. Rahul & Rohit Gosain wrap up their three-part CME series on HER2-positive biliary tract cancer. Joined by Dr. Rachna Shroff, they delved into the critical topic of managing adverse events associated with treatments like TDXD and Zanidatamab. The discussion covered: • Overview of the treatment landscape for biliary tract cancer • Common side effects of TDXD, including interstitial lung disease, nausea, and fatigue • Management strategies for adverse events, including dose reductions and supportive care • Insights on Zanidatamab, its side effects, and infusion-related reactions • The importance of biomarker testing and patient-centered care in treatment decisions Tune in to gain valuable insights on how to improve patient quality of life while navigating the complexities of HER2-positive biliary tract cancer treatments. Follow us on social media: • X/Twitter: https://twitter.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
In this episode of Hema Now, Diu Nguyen joins Jonathan Sackier to discuss breakthroughs in acute myeloid leukaemia (AML) research. From RNA-binding proteins to the future of stem cell-targeted therapies, Nguyen shares the translational goals of her lab and what's on the horizon in AML diagnosis and treatment. Timestamps: 01:20 – Quickfire Insights 03:32 – AML Breakthroughs 04:47 – Leukaemia Surprise 06:42 – Alternate Pathways 07:54 – RNA Differences 12:08 – Diagnostics Future 14:03 – RBMX Spotlight 20:21 – Targeted Therapies 27:07 – Treatment Barriers 31:32 – Three Wishes
This episode features the Beamion LUNG-1 trial, where zongertinib showed a 71% response rate in previously treated HER2-mutant NSCLC patients. The EAGLE-1 trial found gepotidacin non-inferior to standard treatment for urogenital gonorrhoea, with a 92.6% success rate. The U.S. Department of Health and Human Services and NIH launched the Generation Gold Standard initiative, a universal vaccine platform targeting pandemic-prone viruses, with trials ongoing for H5N1 avian influenza and coronaviruses.
Welcome to the Oncology Brothers podcast! In this episode, Drs. Rohit and Rahul Gosain are joined by Dr. Ghassan Abou-Alfa, a medical oncologist specializing in the hepatobiliary space at Memorial Sloan Kettering. Together, they explored the current treatment landscape of biliary tract cancer, focusing on the advancements in HER2-driven therapies. Key topics discussed included: • The evolution of treatment options for biliary tract cancer, including chemotherapy and immunotherapy. • The significance of genetic testing, including IDH1 mutations, FGFR alterations, and HER2 status. • The role of multidisciplinary collaboration in managing hepatobiliary cancers. • Insights into the latest clinical trials and emerging therapies for HER2-positive biliary tract cancer. Join us as we delve into the complexities of biliary tract cancer and the promising developments in HER2-targeted treatments. Don't forget to check out our next episode, where we will take a deeper dive into the data surrounding HER2 therapies and discuss management strategies for common side effects. YouTube: https://youtu.be/pGiU7JJGNOc Follow us on social media: • X/Twitter: https://twitter.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Subscribe to stay updated on the latest in oncology! #OncologyBrothers #BiliaryTractCancer #HER2 #CancerTreatment #MedicalOncology #CME #Podcast
In this episode of Hema Now, Jonathan Sackier is joined by John Riches, Clinical Reader in Cancer Immunometabolism at the Barts Cancer Institute and Honorary Consultant Haemato-oncologist. They explore how metabolic shifts drive lymphoma progression, the potential of immunotherapy, and what the future holds for treating lymphoid malignancies. Timestamps: 00:00 – Introduction 01:46 – Riches' journey into haematology 03:42 – What is T cell exhaustion? 07:06 – The key role of metabolism in lymphoma 09:33 - Richter's syndrome 13:17 – Breakthroughs in immunotherapy 20:27 – The challenges of translational research 25:39 – B cells in autoimmune diseases 28:16 – The potential of breath biopsy 32:58 – Riches' three wishes for healthcare
In this episode, hear Lauren Byers, MD and Christine Hann, MD share their insights on the latest data regarding new therapies targeting B7-H3 in small cell lung cancer including: Rationale for targeting B7-H3Overview of the structure of antibody-drug conjugates (ADCs)Results from the phase I/II IDeate-PanTumor01 trial of ifinatamab deruxtecan (I-DXd) in ES-SCLCData from the phase II IDeate-Lung02 trial of 2 different doses of I-DXd in patients with previously treated ES-SCLCAn overview of the ongoing phase III trials IDeate-Lung02 and IDeate-Lung03 of I-DXd in SCLCEarly phase evidence on other novel B7-H3 ADCs including YL201 and HS-20093Program faculty:Lauren Byers, MDProfessor and Thoracic Section ChiefDepartment of Thoracic/Head and Neck Medical OncologyMD Anderson Cancer CenterHouston, TexasChristine L. Hann, MD, PhDAssociate Professor of OncologyDirector, Small Cell Lung Cancer TherapeuticsJohns Hopkins University School of MedicineBaltimore, Maryland
Jo Cheah talks to Bronwyn Jenkins, consultant neurologist, about the role of calcitonin gene-related peptide (CGRP)–targeted therapies in migraine treatment. Bronwyn explains the difference between tension-type headaches and migraines, and outlines current treatment options. The conversation also covers adverse effects, patient eligibility, and other important considerations for prescribers. Read the full article in Australian Prescriber.
ReferencesSignal Transduction and Targeted Therapy 2019. volume 4, Article number: 7 JAMA. 2024 Dec 10;332(22):1924–1935. ACS Nano , 2025.January 27.Vol 19/Issue 5Guerra, DJ. 2025. Unpublished Lectures.Clapton &Whitlock. 1970."Why does Love have to be so Bad?" on LAYLA lp.https://open.spotify.com/track/6S5DtyJNXTgHEXIVUToAPP?si=e2c45a57168f4f6eAllman, D 1970 "Little Martha" on EAT A PEACH lp.https://open.spotify.com/track/2WPLFvAldG0GG6Ad3Xa0TO?si=8d5e8ed3fa934860Mozart, WA. 1791 "Clarinet Concerto in A Major. K.622https://open.spotify.com/album/5PerO11RxVNvixJPjW4UAl?si=2Jnw72E6QueNO6I9ff6Wzw
00:00 Introduction and Overview of Caristo Diagnostics09:08 The Technology Behind Carry Heart18:00 Clinical Implications and Risk Assessment27:27 Actionable Steps for Patients30:34 Optimizing Cardiovascular Drug Dosing32:31 AI in Cardiovascular Medicine33:50 Leveraging Historical Data for Risk Prediction36:25 AI's Role in Molecular Pathway Analysis39:03 GLP-1 and Cardiovascular Outcomes41:56 Targeted Therapies in Cardiovascular Treatment42:45 Building Trust in New Technologies49:16 Regulatory Approvals and Future Prospects54:15 Expanding Applications Beyond Cardiology57:16 Looking Ahead: The Future of Caristo Diagnostics
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZK865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZK865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZK865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZK865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZK865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.
Drs. Sabari and Yu discuss the molecular landscape of HER2-mutant lung cancer, including its genomic characteristics, common co-mutations, and differences between HER2 mutations and HER2 amplification. This discussion also explores the prevalence and clinical patterns of HER2 mutations, their oncogenic mechanisms, their impact on tumor behavior and metastases, and potential environmental or genetic contributors to their development.
Interview with Timothy M. Pawlik, MD, PhD, MPH, MTS, MBA, author of Molecular Testing and Targeted Therapies in Hepatobiliary Cancers: A Review. Hosted by Amalia Cochran, MD. Related Content: Molecular Testing and Targeted Therapies in Hepatobiliary Cancers
Interview with Timothy M. Pawlik, MD, PhD, MPH, MTS, MBA, author of Molecular Testing and Targeted Therapies in Hepatobiliary Cancers: A Review. Hosted by Amalia Cochran, MD. Related Content: Molecular Testing and Targeted Therapies in Hepatobiliary Cancers
Dermatologic toxicities associated with oncology treatment can significantly impact quality of life and treatment adherence for patients with breast cancer. The Association of Cancer Care Centers (ACCC) is committed to providing up-to-date guidance on managing these dermatologic side effects to enhance clinical outcomes. In this episode of CANCER BUZZ, Allison Gordon, MD, a supportive oncodermatologist at Memorial Sloan Kettering Cancer Center, discusses the dermatologic toxicities associated with breast cancer treatment. Dr Gordon explores preventive measures that oncologists can implement early in the treatment course and offers alternative resources for oncology clinicians when an oncodermatologist referral is not feasible. Additionally, she highlights capivasertib, a recently approved antineoplastic drug, and reviews its associated cutaneous adverse events, along with supportive care and management strategies. Thank you to AstraZeneca for their support of this program. Allison Gordon, MD Dermatologist Memorial Sloan Kettering Cancer Center New York, NY “Because many of these medications can cause dry skin, which can be debilitating for patients... [we recommend] using a thick ointment or cream moisturizer on their damp skin after they shower... it doesn't have to be anything expensive... I always recommend that to all patients regardless of what treatment they're on.”– Allison Gordon, MD Additional Reading/Sources ACCC Supportive Care Strategies for Dermatologic Toxicities Related to Cancer Therapies education program (https://www.accc-cancer.org/home/learn/comprehensive-cancer-care-services/dermatologic-toxicities?) Targeted Therapy Side Effects – American Cancer Society (https://www.cancer.org/cancer/managing-cancer/treatment-types/targeted-therapy/side-effects.html) Oncodermatology: Advancing the Science and Care of Cancer Patients and Survivors (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569770/) Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy (https://ascopubs.org/doi/10.1200/EDBK_289911) Multinational Association of Supportive Care in Cancer (MASCC) Oncodermatolgy Study Group (https://mascc.org/resources/mascc-guidelines/) Guidelines for the Prevention and Treatment of Radiation-Induced Skin Reactions (https://mascc.org/resources/mascc-guidelines/) Guidelines for Prevention and Management of Dermatological Toxicities Related to Anticancer Agents (https://pubmed.ncbi.nlm.nih.gov/33248228/)
What if a cancer treatment worked—until it suddenly didn't? A new case report, “Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report,” published in Oncotarget, reveals how a non-small cell lung cancer (NSCLC) patient developed drug resistance through a rare genetic alteration, allowing the cancer to evade therapy. This unexpected finding highlights the importance of advanced genetic testing and personalized cancer treatments. Non-Small Cell Lung Cancer, Targeted Therapy and Drug Resistance Non-Small Cell Lung Cancer is the most common type of lung cancer, accounting for nearly 85% of all cases. Some patients with NSCLC have genetic mutations, such as ROS1 gene fusions, that drive tumor growth. These patients often respond well to targeted therapies like lorlatinib, a ROS1 inhibitor that blocks cancer growth. However, cancer is constantly evolving. Over time, it can develop resistance to targeted therapies, leading to treatment failure. Understanding these resistance mechanisms is crucial for precision oncology, the approach of tailoring cancer treatment based on a patient's unique genetic profile. Full. blog - https://www.oncotarget.org/2025/03/12/a-rare-genetic-shift-that-helped-lung-cancer-evade-treatment/ DOI - https://doi.org/10.18632/oncotarget.28682 Correspondence to - Wade T. Iams - wade.t.iams@vumc.org Video short - https://www.youtube.com/watch?v=HE_qSkcRZho About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/KRC865. CME credit will be available until February 26, 2026.Modern Practice Principles in Lung Cancer—First Find the Targets, Then Treat With Precision: A Concise Guide for Biomarker Testing and EGFR-Targeted Therapy in NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Both are Johnson & Johnson companies.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/KRC865. CME credit will be available until February 26, 2026.Modern Practice Principles in Lung Cancer—First Find the Targets, Then Treat With Precision: A Concise Guide for Biomarker Testing and EGFR-Targeted Therapy in NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Both are Johnson & Johnson companies.Disclosure information is available at the beginning of the video presentation.
Featuring slide presentations and related discussion from Dr Joyce O'Shaughnessy, Dr Mark Pegram and Prof Peter Schmid, including the following topics: Strategies to Identify Patients with HER2-Low and HER2-Ultralow Breast Cancer (0:00) Case: A woman in her mid 50s initially presenting with ER-positive, HER2 IHC 1+ locally advanced breast cancer who experiences progression to HER2 0 metastatic disease (20:53) Case: A woman in her early 60s with ER-positive, HER2 IHC 1+ metastatic breast cancer (mBC) who experiences disease progression 8 months after starting first-line CDK4/6 and aromatase inhibitor (29:14) Expanding the Spectrum of Targeted Therapy (38:52) Case: A woman in her early 60s with HR-positive, HER2 IHC 1+ mBC who receives fifth-line T-DXd resulting in stable disease (1:04:13) Case: A woman in her early 50s with progressive HR-positive, HER2 IHC 0 mBC and an ESR1 mutation who has ultralow HER2 expression on rebiopsy of new liver lesions (1:12:35) Identification and Management of Adverse Events with T-DXd (1:20:27) Case: A woman in her late 40s with HR-positive, HER2 IHC 2+ mBC who experienced persistent low-grade nausea with T-DXd that resolved with olanzapine (1:34:02) Case: A woman in her early 60s with ER-positive, HER2 2+ mBC who received T-DXd resulting in fatigue and asymptomatic interstitial lung disease (1:48:58) CME information and select publications
Guest Kristy Red-Horse is a biologist who specializes in coronary artery development and disease. She says the latest advances in treatment of blockages could do away with invasive bypass surgeries in favor of growing new arteries using molecules like CXCL12, known to promote artery regrowth in mice. Red-Horse explains how leaps forward in medical imaging, expanding atlases of gene expressions, and new drug delivery mechanisms could someday lead to trials in humans. But, before that day can arrive, much work remains, as Red-Horse tells host Russ Altman in this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your quest. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Kristy Red-HorseKristy's Lab: Red-Horse LabConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces Kristy Red-Horse, a professor of biology at Stanford University.(00:03:46) Replacing Open-Heart SurgeryWhy bypass surgery is invasive, risky, and requires long recovery.(00:05:09) Challenges in Artery GrowthThe difficulty of targeting artery growth with medical interventions.(00:07:32) The Role of Collateral ArteriesDefinition and function of collateral arteries as natural bypass.(00:09:37) Triggers for Natural Bypass FormationGenetic factors that may influence the growth of these bypass arteries.(00:10:49) Unique Properties of Coronary ArteriesChallenges of ensuring artificial growth replicates natural artery function.(00:13:04) The Discovery of CXCL12A key molecule that stimulates collateral artery formation.(00:16:16) Precise Artery Growth ControlThe results of targeted CXCL12 injections into mice hearts.(00:17:32) CXCL12's Overlooked RoleThe molecule's role in the immune system and stem cells.(00:20:27) Guinea Pigs and Heart Attack ResistanceHow guinea pigs naturally develop collaterals.(00:23:19) Preventing Heart DiseaseUsing artery growth treatments to target early-stage coronary disease.(00:25:25) Breakthroughs in Imaging TechnologyNew technology that enables identification of collateral growth pathways.(00:27:07) How Collateral Arteries FormThe two mechanisms in which new arteries form.(00:28:48) The Future of Medical Artery GrowthThe possibility of eliminating bypass surgery with targeted artery growth. Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook
A free way to support your cancer treatment? Shifting your mindset and finding the positives in life. This week, I'm joined by Taylor Dukes, a family nurse practitioner, mother of two, and former colleague. We sat down to discuss her cancer journey—from finding out she had a brain tumor to entering remission—what she's learned in the years since her initial diagnosis, and how reframing her mindset helped her thrive. In this episode, you'll discover: Integrative Approaches to Cancer Treatment: When doctors found a brain tumor in Dukes' right frontal lobe, the mother of two didn't jump straight into surgery. Instead, she implemented a lot of integrative therapies such as coffee enemas, hyperbaric oxygen chamber therapy, wearing a red light helmet, and more. "In the five months between when I got diagnosed and when I actually had surgery, we were able to shrink the brain tumor in half," says Duke." The Power of Positive Thinking: Dukes, who currently has "no evidence of disease," believes that as long as you're breathing, there is always hope and there are always options. "No diagnosis, no test, no statistic has the ability to figure out the number of your days," says Dukes, who credits prayer and meditation for her mindset. "Your mind is powerful and what you believe is so, so powerful." Maintaining Your Health After Cancer: Two years after her diagnosis, Dukes is now in maintenance mode and focuses on getting her immune system back on track. She keeps up with regular fasting, eats a lower-carb diet, and alternates between red light therapy, ozone therapy, and sauna. “I'm starting specific therapies to target the co-infections and Lyme markers I have,” she says. 06:40 A Life-Changing Diagnosis 10:15 Integrative Approach to Healing 18:19 The Power of Faith and Family 20:26 Life After Surgery 24:41 Immune System Suppression and Cancer Growth 25:01 Prevention and Immune System Recovery 25:26 Targeted Therapies and Integrative Approaches 26:55 Conventional vs. Integrative Treatment Options 31:11 Support Systems and Personal Decisions 34:08 Navigating Parenthood During Cancer 37:55 Coping Mechanisms and Emotional Resilience Connect with Dr. Myers: Website: https://www.amymyersmd.com/ Newsletter: https://www.amymyersmd.com/ec/guide-to-leaky-gut Facebook: https://www.facebook.com/AmyMyersMD Instagram: https://www.instagram.com/amymyersmd/ Connect with Taylor Dukes: Website: https://taylordukeswellness.com/ Online store: https://shop.taylordukeswellness.com/collections/all-products Instagram: https://www.instagram.com/taylordukeswellness/ Facebook: https://www.facebook.com/taylordukeswellness/ Tik Tok: https://www.tiktok.com/@taylordukeswellness
© 2020-2025 Ivy Podcast Discovery LLC
